Hepatocyte transplantation for liver‐based metabolic disorders
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Hepatocyte transplantation is being investigated as an alternative to orthotopic liver transplantation in patients with liver‐based metabolic disorders. The progress made in this field to date is reviewed. Protocols have been developed using collagenase perfusion to isolate human hepatocytes from unused donor liver tissue. Hepatocytes with a high viability can often be obtained and can be cryopreserved for later use, though with loss of function on thawing. For clinical use, hepatocytes must be prepared in clean GMP conditions with cells meeting criteria of function and lack of microbial contamination before patient use. Hepatocytes are infused intraportally into the patient's liver, where a proportion of cells will engraft and replace the deficient metabolic function without the need for major surgery. Twenty patients have now received hepatocyte transplantation, including eight children at King's College Hospital. There was a range of aetiologies of liver disease: familial hypercholesterolaemia, Crigler–Najjar syndrome type 1, urea cycle defects, infantile Refsum disease, glycogen storage disease type Ia, inherited factor VII deficiency and progressive familial intrahepatic cholestasis type 2. Clinical improvement and partial correction of the metabolic abnormality was observed in most cases. Considerable progress has been made in developing the technique, but hepatocyte transplantation is limited by the available supply of liver tissue. Hepatocytes derived from stem cells could provide alternative sources of cells in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells
Fausto, N. (2004) · Hepatology · doi:10.1002/hep.20214 · Cited by 720 · cited 2×
“There is no doubt that stem cells/stem cell-derived hepatocytes should offer the potential to overcome the current limitations of both supply of hepatocytes and the extent of repopulation of the liver after transplantation (Fausto 2004).”
BackgroundIsolated Hepatocyte Transplantation in an Infant With a Severe Urea Cycle Disorder
Horslen, S. P., McCowan, T. C., Goertzen, T. C., Warkentin, P. I., Cai, H. B., Strom, S. C., & Fox, I. J. (2003) · Pediatrics · doi:10.1542/peds.111.6.1262 · Cited by 295 · cited 1×
“…has been used as a treatment for liver-based metabolic diseases such as Crigler–Najjar syndrome type I (Fox et al 1998), glycogen storage disease type 1a (Muraca et al 2002), urea cycle defects (Horslen et al 2003) and congenital deficiency of coagulation factor VII (Dhawan et al 2004).”
MethodDe Vree, J. M. L., Ottenhoff, R., Bosma, P. J., Smith, A. J., Aten, J., & Oude Elferink, R. P. J. (2000) · Gastroenterology · doi:10.1053/gast.2000.20222 · Cited by 186 · cited 2×
“nale was that the injected hepatocytes would have a selective advantage over the patients’ own defective hepatocytes to repopulate the native liver, as had been shown in a mouse model of progressive familial intrahepatic cholestasis ( De Vree et al 2000 ), where up to 70% of host hepatocytes were replaced with donor c…”
BackgroundHorslen, S. P., & Fox, I. J. (2004) · Transplantation · doi:10.1097/01.tp.0000113809.53415.c2 · Cited by 119
Cited by
Suggested guidelines for the diagnosis and management of urea cycle disorders
Häberle, J., Boddaert, N., Burlina, A., Chakrapani, A., Dixon, M., Huemer, M., Karall, D., Martinelli, D., Crespo, P., Santer, R., et al. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-32 · Cited by 628
Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets
Ohashi, K., Yokoyama, T., Yamato, M., Kuge, H., Kanehiro, H., Tsutsumi, M., Amanuma, T., Iwata, H., Yang, J., Okano, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1576 · Cited by 507
Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision
Häberle, J., Burlina, A., Chakrapani, A., Dixon, M., Karall, D., Lindner, M., Mandel, H., Martinelli, D., Pintos‐Morell, G., Santer, R., et al. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12100 · Cited by 506
Human hepatocyte transplantation: current experience and future challenges
Dhawan, A., Puppi, J., Hughes, R. D., & Mitry, R. R. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.44 · Cited by 362
“Hepatocyte transplantation is a promising alternative to OLT for the treatment of some liver-based metabolic disorders or acute liver failure”
BackgroundSelf-citationSurvival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders
Enns, G. M., Berry, S. A., Berry, G. T., Rhead, W. J., Brusilow, S. W., & Hamosh, A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066596 · Cited by 355
Metadata
- Authors
- Dhawan, A., Mitry, R. R., & Hughes, R. D.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2006-04
- Volume
- 29
- Issue
- 2-3
- Pages
- 431-435
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2021718747
- Cited by
- 195
- References
- 4
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.